Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years

Next Previous
X
Search
Trial Profile

A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLA 1553 (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions
  • Sponsors Valneva

    • Most Recent Events

    • 05 Jul 2021 According to an Valneva media release, Prof. Thomas Jelinek, will present the data from this trial at a virtual symposium titled, Developing new vaccines to protect against infectious diseases at home and abroad on July 9, 2021 at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
    • 08 Sep 2020 According to a Valneva media release, this study served as a basis for the companys End of Phase 2 meeting with the U.S. FDA and supported the direct progression into Phase 3.
    • 02 Jun 2020 According to a Valneva media release, full data from this trial were published in the peer-reviewed medical journal The Lancet Infectious Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top